Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Account Payables
Amounts the company owes suppliers for goods and services received.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 75.8% from a year ago
Account payables stood at $4.49M at the end of Q1 FY2026, up 75.8% from a year earlier and up 116.8% from the prior quarter. Over 3 fiscal years it compounded at +100.0% a year.
Context
- Account payables amounted to 4.6% of total assets at the end of Q1 FY2026, up 2.9 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +75.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 2.07M USD
- Year-over-year change
- -9.8%
- 3-year CAGR
- +100.0%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.07M | -9.8% |
| FY2024 | 2024-12-31 | 2.3M | +122.0% |
| FY2023 | 2023-12-31 | 1.04M | +299.6% |
| FY2022 | 2022-12-31 | 259K | — |
Account Payables vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 account payables of $4.49M is the 2nd highest of the 11 companies compared; the peer median is $2M.
- Its year-over-year change of +75.8% is the highest of 10, against a peer median of -8.3%.
- Account payables amounts to 4.6% of total assets for AARD, versus a peer median of 1.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $4.99M | +75.3% | +15.3% | 7.8% | |
| Mar 2026 | $4.49M | +75.8% | +100.0% | 4.6% | |
| Mar 2026 | $4.36M | -8.3% | -31.3% | 1.4% | |
| Mar 2026 | $3.5M | -9.6% | +71.5% | 2.4% | |
| Mar 2026 | $3.32M | -18.5% | -7.6% | 1.5% | |
ZURAZura Bio Limited | Mar 2026 | $2.08M | +66.8% | -14.0% | 0.9% |
| Mar 2026 | $1.91M | -62.2% | -28.0% | 1.4% | |
| Mar 2026 | $1.19M | +41.0% | -9.5% | 0.7% | |
| Mar 2026 | $1.13M | +29.0% | -22.3% | 0.5% | |
| Mar 2026 | $356K | -47.7% | -63.8% | 0.4% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding AARD) | $2M | -8.3% | -14.0% | 1.1% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.